Skip to content

oral melatonin in the treatment of acute respiratory distress syndrome

The effect of oral melatonin in the treatment of acute respiratory distress syndrome in neonates

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130308012743N3
Enrollment
74
Registered
2022-11-13
Start date
2022-08-23
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distress syndrome of neonates. P22.0Respiratory distress syndrome of newborn

Interventions

Intervention 1: Intervention group: The intervention group will include infants who, in addition to the standard treatment, will be treated with oral melatonin at a dose of 10 mg/kg per day for three

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 30 Days

Inclusion criteria

Inclusion criteria: Infants with respiratory distress syndrome with any grade of respiratory distress

Exclusion criteria

Exclusion criteria: Neonatal sepsis Neonates with Respiratory distress disease other than RSD Neonates with cardiovascular diseases or diseases of the central nervous system Neonates with kidney failure

Design outcomes

Primary

MeasureTime frame
Pro-antioxidant. Timepoint: Laboratory examination is done on the first and third day of birth. Method of measurement: By measuring pro-antioxidant test.;C-reactive protein factor (CRP). Timepoint: Laboratory examination is done on the first and third day of birth. Method of measurement: By measuring CRP.;Respiratory distress score. Timepoint: Laboratory examination is done on the first and third day of birth. Method of measurement: By Measuring Respiratory distress score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Mousavi

Mashhad University of Medical Sciences

dr.farnazmousavi@gmail.com+98 51 3852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026